adMare Bio Innovations
VC Fund
Vancouver, Canada
adMare Bio innovations is a global life sciences venture, building Canadian life sciences from sea to sea.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries adMare Bio Innovations invests in
Stages adMare Bio Innovations invests in
Countries adMare Bio Innovations invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gordon McCauley
|
|||
Lana Janes
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 10 (71%)
- Therapeutics 4 (29%)
- Pharmaceutical 3 (21%)
- Health Care 2 (14%)
- Life Science 2 (14%)
Stage
- Seed 3 (21%)
- Series B 3 (21%)
- Series A 2 (14%)
- Funding Round 2 (14%)
- Pre-Seed 1 (7%)
Country
- Canada 7 (50%)
- France 1 (7%)
- United States 1 (7%)
- United Kingdom 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Gordon McCauley
President & CEO
|
President & CEO | Total investments: 0 | Find email | |
|
Lana Janes
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kainova Therapeutics
|
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M / Series B / Feb 09, 2026 | |
Find therapeutics
|
Find therapeutics provides biotechnology research services. They also provide CTI life sciences, frontiers of therapy, treat inflammatory autoimmune diseases, domain therapeutics, and GPCR technology services. | $7.2M / Series A / Jan 09, 2026 | |
Thryv Therapeutics
|
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | Sep 17, 2025 | |
KisoJi Biotechnology
|
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. | $40.6M / Series B / Dec 02, 2024 | |
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | |
|
Find therapeutics
|
Find therapeutics provides biotechnology research services. They also provide CTI life sciences, frontiers of therapy, treat inflammatory autoimmune diseases, domain therapeutics, and GPCR technology services. | $8.1M / Convertible Note / Sep 16, 2024 | |
|
Specific Biologics
|
Specific Biologics' mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body. | Seed / Oct 10, 2023 | |
Inversago Pharma
|
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | |
Immugenia
|
Immugenia is an early-stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses. | Pre-Seed / Oct 06, 2022 | |
|
Kainova Therapeutics
|
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $41.1M / Series A / May 10, 2022 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does adMare Bio Innovations invest in?
adMare Bio Innovations invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Seed and Series B stage. Most of the 14 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact adMare Bio Innovations?
Public channels for adMare Bio Innovations include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at adMare Bio Innovations?
The team at adMare Bio Innovations includes Gordon McCauley (President & CEO) and Lana Janes (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
